ArticleBone reports2026
Assessing cortical bone changes with Romosozumab after one year: Insights from an exploratory HR-pQCT study.
Article in Bone reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Romosozumab does not improve volumetric bone mineral density at distal radius but is associated with early changes in bone strength: a prospective study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To describe changes in bone microarchitecture after 6 and 12 months of romosozumab (ROMO), identify responders based on cortical thickness (Ct.Th) increase at the distal radius (≥3% at 12 months), and explore factors associated with treatment response. Methods: We conducted a prospective cohort study of postmenopausal women with osteoporosis at very high fracture risk who started ROMO between August 2021 and February 2023. HR-pQCT, BMD, and bone turnover markers were assessed at baseline, 6, and 12 months. Patients were classified as responders or non-responders based on 12-month Ct.Th changes. Results: Sixteen patients were analyzed. Although improvements in distal tibial microarchitecture were observed at 12 months, treatment responses were heterogeneous. Nine patients were classified as responders and seven as non-responders. Baseline characteristics were similar, though responders had lower trabecular bone parameters at the distal radius. At 12 months, responders showed significant gains in Ct.Th and cortical area at both distal tibia (+5% and + 5%) and radius (+7% and + 6%), while non-responders showed no improvement or decline. These trends were evident by 6 months. Lumbar spine and hip BMD increased significantly only in responders (+14% and + 6%). PTH levels rose in both groups at 6 months but continued increasing only in non-responders, despite comparable vitamin D status. Conclusion: By stratifying patients based on Ct.Th changes, we identified treatment responders (56%) with rapid cortical bone improvements detectable at 6 monthsIdentifying clinical predictors of ROMO responsiveness and determining whether shorter treatment durations may be justified in selected patients warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.